U.S. Pulmonary Arterial Hypertension Market Size & Outlook
U.S. pulmonary arterial hypertension market, 2018-2030 (US$M)
Related Markets
U.S. pulmonary arterial hypertension market highlights
- The U.S. pulmonary arterial hypertension market generated a revenue of USD 2,772.0 million in 2023 and is expected to reach USD 3,829.1 million by 2030.
- The U.S. market is expected to grow at a CAGR of 4.7% from 2024 to 2030.
- In terms of segment, prostacyclin and prostacyclin analogs was the largest revenue generating drug class in 2023.
- SGC Stimulators is the most lucrative drug class segment registering the fastest growth during the forecast period.
Pulmonary arterial hypertension market data book summary
| Market revenue in 2023 | USD 2,772.0 million |
| Market revenue in 2030 | USD 3,829.1 million |
| Growth rate | 4.7% (CAGR from 2023 to 2030) |
| Largest segment | Prostacyclin and prostacyclin analogs |
| Fastest growing segment | SGC Stimulators |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators |
| Key market players worldwide | United Therapeutics Corp, Bayer AG, Gilead Sciences Inc, Johnson & Johnson, Viatris Inc, GlaxoSmithKline, Sandoz Group AG ADR, Lupin, Sun Pharmaceutical Industries, Teva Pharmaceutical Industries Ltd |
Other key industry trends
- In terms of revenue, U.S. accounted for 37.6% of the global pulmonary arterial hypertension market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. pulmonary arterial hypertension market is projected to lead the regional market in terms of revenue in 2030.
- Canada is the fastest growing regional market in North America and is projected to reach USD 675.3 million by 2030.
Prostacyclin and prostacyclin analogs was the largest segment with a revenue share of 47.47% in 2023. Horizon Databook has segmented the U.S. pulmonary arterial hypertension market based on endothelin receptor antagonists (eras), pde-5 inhibitors, prostacyclin and prostacyclin analogs, sgc stimulators covering the revenue growth of each sub-segment from 2018 to 2030.
The U.S. is market leader in the PAH drugs, accounting for USD 2,772.17 Million in 2020 and anticipated to grow at a rate of 4.2% over the forecast period. Availability, of branded drugs in the U.S. coupled with supportive legislation for rare diseases and orphan drugs contributed remunerative growth of this region.
The Orphan Drug Act (ODA) 1983, and Rare Disease Act 2002 are the two most important acts that facilitate the ethical distribution and usage of orphan drugs. With the help of organizations such as the National Organization of Rare Disorders, the development of orphan drugs is promoted, which have a smaller market share.
Several companies are undertaking initiatives related to progress in the pulmonary arterial hypertension market. For instance, in June 2020, Bayer U.S. launched the Second Annual Pulmonary Hypertension Accelerated Bayer Awards to support, encourage, and recognize innovation in research in Pulmonary Hypertension (PH).
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Pulmonary Arterial Hypertension Market Scope
Pulmonary Arterial Hypertension Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. pulmonary arterial hypertension market size, by drug class, 2018-2030 (US$M)
U.S. Pulmonary Arterial Hypertension Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
